Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms
Phase 3
Completed
- Conditions
- Interventions
- Drug: Placebo tamsulosin hydrochloride OCAS 0.4 mgDrug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mgDrug: Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mgDrug: tamsulosin hydrochloride OCAS 0.4 mgDrug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1334
- Registration Number
- NCT01018511
Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes
- First Posted Date
- 2009-10-14
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1276
- Registration Number
- NCT00994292
A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2015-10-27
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 1992
- Registration Number
- NCT00902928
Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-08-25
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 49
- Registration Number
- NCT00673725
© Copyright 2024. All Rights Reserved by MedPath